^P.H. and Horhammer, L., Hager's Handbuch der Pharmazeutischen Praxis, Vols. 2-6, Springer-Verlag, Berlin, 1969-1979
^Tarragó, T; Kichik, N; Claasen, B; Prades, R; Teixidó, M; Giralt, E (2008). “Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor”. Bioorganic & medicinal chemistry16 (15): 7516–24. doi:10.1016/j.bmc.2008.04.067. PMID18650094.
^Weng, Zi-Miao, et al. (2017). “Structure-activity relationships of flavonoids as natural inhibitors against E. ácoli β-glucuronidase”. Food and Chemical Toxicology109: 975-983. doi:10.1016/j.fct.2017.03.042.
^Bao, Minglong, et al. (2022). “Research progress on pharmacological effects and new dosage forms of baicalin”. Veterinary Medicine and Science8 (6): 2773-2784. doi:10.1002/vms3.960.